PMID- 16080566
OWN - NLM
STAT- MEDLINE
DCOM- 20050920
LR  - 20211203
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 25
IP  - 4
DP  - 2005 Jul-Aug
TI  - Investigation of HER2 overexpression in non-small cell lung cancer.
PG  - 3061-6
AB  - Lung cancer is the leading cause of mortality worldwide. The median survival of 
      advanced disease is in the range of 8 to 10 months. Intrinsic or acquired drug 
      resistance pose major challenges to the success of chemotherapy. The HER2 gene, 
      also known as c-erbB-2 or neu, is a proto-oncogene that encodes a membrane-bound 
      receptor tyrosine kinase of the epithelial growth factor receptor (EGFR) family. 
      It has a possible role in tumor cell proliferation, tumor invasion, tumor 
      metastasis and drug resistance. We retrospectively investigated 88 samples of 
      non-small cell lung cancer (NSCLC) and assessed the correlation between HER2 
      expression and tumor histology. The expression of HER2 protein was analyzed by 
      immunohistochemical staining (IHC) and HER2 DNA amplification was detected by 
      using fluorescence in situ hybridization (FISH). HER2 overexpression (2+, 3+) was 
      detected in 5 (5.7%) out of 88 specimens. All of the HER2-overexpressing tumors 
      histologically proved to be squamous cell carcinoma (SCC). Cases with 2+ HER2 
      immunoreactivity showed either no amplification (3.875 and 2.525), or borderline 
      amplification (4.75). Cases with 3+ HER2 immunoreactivity showed moderate 
      amplification (7.35) and strong amplification (15-20 - cluster), respectively. 
      The HER2 expression in NSCLC was relatively low in the selected Hungarian 
      population; consequently, there is no indication for introduction of trastuzumab 
      for the treatment of lung cancer.
FAU - Ugocsai, Katalin
AU  - Ugocsai K
AD  - Department of Medical Microbiology and Immunbiology, Faculty of General Medicine, 
      University of Szeged, Hungary.
FAU - Mandoky, Laszlo
AU  - Mandoky L
FAU - Tiszlavicz, Laszlo
AU  - Tiszlavicz L
FAU - Molnar, Joseph
AU  - Molnar J
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/pathology/therapy
MH  - Combined Modality Therapy
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/genetics/*metabolism/pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proto-Oncogene Mas
MH  - Receptor, ErbB-2/*biosynthesis/genetics
MH  - Retrospective Studies
EDAT- 2005/08/06 09:00
MHDA- 2005/09/21 09:00
CRDT- 2005/08/06 09:00
PHST- 2005/08/06 09:00 [pubmed]
PHST- 2005/09/21 09:00 [medline]
PHST- 2005/08/06 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2005 Jul-Aug;25(4):3061-6.